

Supplementary Table 3. List of excluded studies after full-text screening

#	Authors	Title	Source	Reasons for exclusion
1	Accinelli, R. A.; Zhang Xu, C. M.; Ju Wang, J. D.; Yachachin-Chavez, J. M.; Caceres-Pizarro, J. A.; Tafur-Bances, K. B.; Flores-Tejada, R. G.; Paiva-Andrade, A. C.	COVID-19: The novel SARS-CoV-2 pandemic. [Spanish]	http://dx.doi.org/10.17843/RPMESP.2020.372.5411	Other than English or Korean
2	Ahmadikia, K.; Mahmoudi, S.; Hassanali, F.; Keshavarz, M.; Mirhendi, H.; Malekzadeh, E.	A Review on the diagnostic approaches of COVID-19 infection; Features and limitations. [Persian]	http://dx.doi.org/10.22122/ijms.v39i611.13023	Other than English or Korean
3	Albani, F.; Sepe, L.; Fusina, F.; Prezioso, C.; Baronio, M.; Caminiti, F.; Di Maio, A.; Faggian, B.; Franceschetti, M. E.; Massari, M.; Salvaggio, M.; Natalini, G.	Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study	10.1016/j.eclim.2020.100562	Not RCTs or observational studies without control group
4	Alvarez-Rodriguez, E.; Gonzalez Gonzalez, R.; Torres-Garate, R.; Lopez Riquelme, P.; Gonzalez Martil, I.; Abad Curnado, V.	Learning with COVID-19: What about anticoagulation?. [Spanish]	http://dx.doi.org/10.23938/ASSN0884	Other than English or Korean
5	Arsentieva, N. A.; Liubimova, N. E.; Batsunov, O. K.; Korobova, Z. R.; Stanevich, O. V.; Lebedeva, A. A.; Vorobyov, E. A.; Vorobyova, S. V.; Kuliikov, A. N.; Lioznov, D. A.; Sharapova, M. A.; Pevtsov, D. E.; Totolian Areg, A.	Plasma cytokines in patients with COVID-19 during acute phase of the disease and following complete recovery. [Russian]	http://dx.doi.org/10.15789/1563-0625-PCI-2312	Other than English or Korean
6	Arslian, Y.; Yilmaz, G.; Dogan, D.; Hasirci, M.; Cetindogan, H.; Ocaj, N.; Savasci, U.; Fidan, G.; Tasci, C.	The effectiveness of early anticoagulant treatment in Covid-19 patients	10.1177/0268355520975595	Not RCTs or observational studies without control group
7	Attila, T.; Sandor, S.	Age-dependent possible role of contact-activated blood coagulation factor XII as a potential contributor to the "bradykinin storm" in COVID-19 patients. [Hungarian]	http://dx.doi.org/10.1556/650.2020.32075	Other than English or Korean
8	Bai, H.; Shen, L.; Chen, X.; Gong, J.; Liu, W.; Sun, Z.; Tang, N.	The prognosis value of PT, DD and PLT and validation of the efficacy of the SIC score on initiating anticoagulant therapy in severe COVID-19 patients. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn114452-20200323-00290	Other than English or Korean
9	Balint, P.; Gyorgy, H.; Miklos, M.	Colon cancer during the coronavirus pandemic - Recovery from COVID-19 pneumonia of an elderly woman with multiple co-morbidities. [Hungarian]	http://dx.doi.org/10.1556/650.2020.31866	Other than English or Korean
10	Ballve-Martin, A.; Boned, S.; Rubiera, M.	Thrombotic complication of severe COVID-19 pneumonia: stroke due to atypical paradoxical embolism. [Spanish]	http://dx.doi.org/10.33588/RN.7105.2020317	Other than English or Korean
11	Ballve-Martin, A.; Boned, S.; Rubiera, M.	[Thrombotic complication of severe COVID-19 pneumonia: stroke due to atypical paradoxical embolism]	10.33588/rn.7105.2020317	Other than English or Korean
12	Bartovska, Z.; Andrie, F.; Beran, O.; Zlamal, M.; Rezac, D.; Murinova, I.; Holub, M.	Data from the first wave of covid-19 from the central military hospital, Prague, Czech Republic. [Czech]	Epidemiol Mikrobiol Immunol . 2020 Winter;69(4):164-171.	Other than English or Korean
13	Benito, N.; Filella, D.; Mateo, J.; Fortuna, A. M.; Gutierrez-Alliende, J. E.; Hernandez, N.; Gimenez, A. M.; Pomar, V.; Castellvi, I.; Corominas, H.; Casademont, J.; Domingo, P.	Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19	10.3389/fmed.2020.00557	Not intervention

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
14	Bikdeli, B.; Jimenez, D.; Adarraga, D.; Aibar, J.; Baeza, C.; Ballaz, A.; Barba, R.; Blanco-Molina, A.; Botella, E.; Criado, J.; Demelo-Rodriguez, P.; Diaz-Brasero, A. M.; de Ancos, C.; del Toro, J.; Farfan-Sedano, A. I.; Fernandez-Capitan, C.; Fidalgo, A.; Flores, K.; Gabara, C.; Galeano-Valle, F.; Gavin-Sebastian, O.; Gil-Diaz, A.; Jara, M. J.; Jara-Palomares, L.; Jimenez, R.; Lainez-Justo, S.; Latorre, A.; Lecumberri, R.; Llamas, P.; Lobo, J. L.; Lopez-Jimenez, L.; Loureiro, B.; Madridano, O.; Mancebo-Plaza, A. B.; Martin del Pozo, M.; Monreal, M.; Munoz-Rivas, N.; Nunez-Fernandez, M. J.; Olivera, P. E.; Ordieres-Ortega, L.; Padin-Paz, E. M.; Pedrajas, J. M.; Quintana-Diaz, M.; Rios-Prego, M.; Rodriguez-Chiaradia, D. A.; Ruiz-Artacho, P.; Siguenza, P.; Surinach, J. M.; Trujillo-Santos, J.; Zamora, C.; Bucherini, E.; Di Micco, P.; Imbalzano, E.; Siniscalchi, C.; Bosevski, M.; Stevanovic, M.; Paz-Rios, L.; Weinberg, I.	Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis	http://dx.doi.org/10.1111/jth.15400	Not outcome
15	Billett, H. H.; Reyes-Gil, M.; Szymanski, J.; Ikemura, K.; Stahl, L. R.; Lo, Y.; Rahman, S.; Gonzalez-Lugo, J. D.; Kushnir, M.; Barouqa, M.; Golestaneh, L.; Bellin, E.	Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality	10.1055/s-0040-1720978	Not intervention
16	Blagova, O. V.; Varionchik, N. V.; Beraia, M. M.; Zaidenov, V. A.; Kogan, E. A.; Sarkisova, N. D.; Nedostup, A. V.	COVID-19 pneumonia in patients with chronic myocarditis (hcv-associated with infarct-like debate): specifics of the diseases course, the role of the basic therapy (Part II). [Russian]	http://dx.doi.org/10.20996/1819-6446-2020-10-03	Other than English or Korean
17	Bolzetta, F.; Maselli, M.; Formilan, M.; Busonera, F.; Albanese, P.; Chiaromanni, F.; Romano, A.; Veronese, N.	Prophylactic or therapeutic doses of heparins for COVID-19 infection? A retrospective study	10.1007/s40520-020-01750-6	Not RCTs or observational studies without control group
18	Bovet, M.; Wadsack, D.; Kosely, F.; Zink, W.; Zahn, R.	Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm: Perimyocarditis and coagulopathy after administration of tocilizumab. [German]	http://dx.doi.org/10.1007/s00101-020-00871-x	Other than English or Korean
19	Bovt, E. A.; Brazhnik, V. A.; Bulanov, A. Yu.; Vasilyeva, E. Yu.; Vuimo, T. A.; Zateyshchikov, E. N.; Lipets, D. A.; Karamzin, S. S.; Lysenko, M. A.; Morozova, D. A.; Nechipurenko, D. Yu.; Pisaryuk, A. S.; Prottsenko, D. A.; Pyregov, A. V.; Rumyantsev, S. A.; Spiridonov, I. S.; Tsarenko, S. V.; Shakhidzhanov, S. S.; Ataulakhonov, F. I.; Rumyantsev, A. G.	Results of multicenter monitoring of hemostasis parameters in patients with covid-19. [Russian]	http://dx.doi.org/10.24110/0031-403X-2020-99-6-62-73	Other than English or Korean
20	Bozzani, A.; Arici, V.; Tavazzi, G.; Boschini, S.; Guglielmi, A.; Mazza, G.; Mojoli, F.; Bruno, R.; Ragni, F.; Sterpetti, A. V.	A simple prognostic score for COVID-19 hospitalized patients developing deep vein thrombosis	http://dx.doi.org/10.1177/02683555211030099	Not intervention
21	Bregel, L. V.; Kostik, M. M.; Fell, L. Z.; Efreanova, O. S.; Soboleva, M. K.; Krupskaya, T. S.; Matyunova, A. E.	Kawasaki disease and multisystem inflammatory syndrome in children with covid-19 infection. [Russian]	http://dx.doi.org/10.24110/0031-403X-2020-99-6-209-219	Other than English or Korean
22	Buennen, A. G.; Sinkeldam, M.; Maas, M. L.; Verdonschot, M.; Wever, P. C.	Prior use of anticoagulation is associated with a better survival in COVID-19	http://dx.doi.org/10.1007/s11239-021-02486-4	Not RCTs or observational studies without control group
23	Burger, A. L.; Kaufmann, C. C.; Jager, B.; Wojta, J.; Farhan, S.; Huber, K.	Course and therapy of cardiovascular diseases during COVID-19 pandemic. [German]	Journal fur Kardiologie 2021, 28(1-2):10-13.	Other than English or Korean
24	B jti, P. P.; Stang, R.; Gunda, B.; Sipos, I.; Bereczki, D.	[Effects of COVID-19 pandemic on acute ischemic stroke care. A single-centre retrospective analysis of medical collateral damage]	10.1556/650.2020.31936	Other than English or Korean

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
25	Carrillo-Esper, R.; Melgar-Biberach, R. E.; Jacinto-Flores, S. A.; Tapia-Salazar, M.; Campa-Mendoza, A. N.	Alterations in coagulation in COVID-19. [Spanish]	http://dx.doi.org/10.24875/CIRU.20000416	Other than English or Korean
26	Castro, H. M.; Canale, H. L.; Ferreyro, B. L.; Prieto, M. A.; Massimino, B. E.; Funtowicz, G.; Fucada, J. M.	Clinical characteristics of coronavirus disease 2019 in a single center of argentina. Retrospective cohort. [Spanish]	Medicina (Argentina) 2020, 80(Supplement 6):35-43.	Other than English or Korean
27	Cecilia, O.; Beata, O.; Reka, F.; Karoly, H.; Erzebet, S.; Nikolett, K.; Peter, H.	SARS-CoV-2-associated inflammatory multisystem disease in a 15-year-old boy. [Hungarian]	http://dx.doi.org/10.1556/650.2021.32129	Other than English or Korean
28	Chancay, J. V.; Guerrero, I. M.; Quelal, E. F.; Gualpa, D. P.; Haro, T. B.; Torres, L. M.; Monar, L. T.; Uvidia, V. C.	Covid-19 and cardiovascular disease: An underestimated link?. [Spanish]	http://dx.doi.org/10.5281/zenodo.4526112	Other than English or Korean
29	Chang, H.; Rockman, C. B.; Jacobowitz, G. R.; Speranza, G.; Johnson, W. S.; Horowitz, J. M.; Garg, K.; Maldonado, T. S.; Sadek, M.; Barfield, M. E.	Deep vein thrombosis in hospitalized patients with coronavirus disease 2019	10.1016/j.jvs.2020.09.010	Not intervention
30	Chen, Y.; Wang, K.; Luo, Y.; Wang, B.; Zhang, M.; Xu, Y.; Yang, Y.; Ma, Y.	Predictive value of neutrophil/lymphocyte ratio on myocardial injury in severe COVID-19 patients. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn112148-20200422-00336	Other than English or Korean
31	Chocron, R.; Galand, V.; Cellier, J.; Gendron, N.; Pommier, T.; Bory, O.; Khider, L.; Trimaille, A.; Goudot, G.; Weizman, O.; Alsac, J. M.; Geneste, L.; Schmeltz, A.; Panagides, V.; Philippe, A.; Marsou, W.; Abdallah, I. B.; Denev, A.; El Batti, S.; Attou, S.; Juvin, P.; Delmotte, T.; Messas, E.; Pezel, T.; Pianquette, B.; Duceau, B.; Gausserm, P.; Sutter, W.; Sanchez, O.; Waldman, V.; Diehl, J. L.; Mirault, T.; Bonnet, G.; Cohen, A.; Smaadja, D. M.	Anticoagulation before hospitalization is a potential protective factor for COVID-19: Insight from a French multicenter cohort study	http://dx.doi.org/10.1161/JAHA.120.018624	Not RCTs or observational studies without control group
32	Contou, D.; Pajot, O.; Cally, R.; Logre, E.; Fraise, M.; Mentec, H.; Plantefeve, G.	Pulmonary embolism or thrombosis in ARDS COVID-19 patients: A French monocenter retrospective study	http://dx.doi.org/10.1371/journal.pone.0238413	Not intervention
33	Corriger, J.; Rein, C.; Salvadori, P.; Villena, A. M.; Cinquetti, G.	Non-intensive care of COVID-19 patients: treatment plan and therapeutic orientations. [French]	http://dx.doi.org/10.1016/S0038-0814(20)29302-43-7	Other than English or Korean
34	Corriger, J.; Rein, C.; Salvadori, P.; Villena, A. M.; Cinquetti, G.	[Non-intensive care of COVID-19 patients: treatment plan and therapeutic orientations]	10.1016/S0038-0814(20)30243-7	Other than English or Korean
35	Corrochano, M.; Acosta-Isaac, R.; Mojal, S.; Miquelez, S.; Rodriguez, D.; Quijad-Manuitt, M.A.; Fraga, E.; Castillo-Ocana, M.; Amaro-Hosey, K.; Albiol, N.; Soria, J. M.; Antonijóan, R. M.; Souto, J. C.	Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19	10.1007/s11239-021-02507-2	Not intervention
36	Ctri,	Role of female sex hormone in COVID 19 patients	http://www.who.int/trialsearch/Trial2.aspx?trialID=CTRI/2020/09/027622	Ongoing studies
37	Ctri,	Role of Heparin inhalation in reducing the duration the patient is breathing with the help of a ventilator	http://www.who.int/trialsearch/Trial2.aspx?trialID=CTRI/2020/11/029175	Ongoing studies
38	Cui, L. L.; Miao, M. S.	Analysis of antithrombotic medication of traditional Chinese medicine based on data mining and network pharmacology. [Chinese]	http://dx.doi.org/10.7501/jissn.0253-2670.2021.04.020	Other than English or Korean
39	Deenstra, D. D.; Nijziel, M. R.; Aldenkamp, A. F.; van Balkom, R. H. H.; Smeenk, Fwjm	[Progression of dyspnea in COVID-19 patients: now what?]	Ned Tijdschr Geneeskd 2020, 164.	Other than English or Korean
40	Desai, A.; Voza, G.; Paiardi, S.; Teofilo, F. I.; Caltagirone, G.; Pons, M. R.; Aloise, M.; Kogan, M.; Tommasini, T.; Savevski, V.; Stefanini, G.; Angelini, C.; Ciccarelli, M.; Badalamenti, S.; De Nalda, A. L.; Aghemo, A.; Ceconi, M.; Martinelli, Boneschi, F.; Voza, A.	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy	10.1016/j.jicard.2020.09.062	Not comparator

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
41	Dumantepe, M.; Aydın, S.; Yildiz, E.; Okur, H. K.; Kocagoz, A. S.; Gundogdu, Y.; Okten, M.; İsbir, S.; Karabulut, H.	Subsegmental Thrombus in COVID-19 Pneumonia: Immunothrombosis or Pulmonary Embolism? Data Analysis of Hospitalised Patients With Coronavirus Disease	http://dx.doi.org/10.1016/j.hlc.2020.08.003	Not comparator
42	Engelen, M. M.; Vandenbrielle, C.; Balthazar, T.; Claeys, E.; Gunst, J.; Guler, I.; Jacquemin, M.; Janssens, S.; Lorent, N.; Liesenborgs, L.; Peerlinck, K.; Pieters, G.; Rex, S.; Simonuel, P.; Van Der Linden, L.; Van Laer, C.; Vos, R.; Wauters, J.; Wilmer, A.; Verhamme, P.; Vanassche, T.	Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization	http://dx.doi.org/10.1055/s-0041-1727284	Not population
43	Eremeeva, D. R.; Bezhenar, V. F.; Zainulina, M. S.; Globa, Y. S.	Pathogenesis of COVID-19. Role of heparins in the therapy of severe conditions in patients with COVID-19. [Russian]	http://dx.doi.org/10.18565/aig.2020.12.25-33	Other than English or Korean
44	Esendagli, D.; Tek, K.; Darilmaz Yuce, G.; Hekimoglu, K.; Ulubay, G.	Nowadays covid underestimates the other suspects. [Turkish]	http://dx.doi.org/10.5578/tt.69953	Other than English or Korean
45	Euctr, D. E.	Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infection	http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001310-38-DE	Ongoing studies
46	Euctr, D. E.	Clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19	http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001936-86-DE	Ongoing studies
47	Euctr, D. E.	Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT)	http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002282-33-DE	Ongoing studies
48	Euctr, D. E.	Hamburg Edoxaban forR anticoagulation in Covid-19 study	http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002504-39-DE	Ongoing studies
49	Euctr, E. S.	Study of antithrombin as prophylaxis of acute respiratory disease in patients with COVID-19	http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001659-42-ES	Ongoing studies
50	Euctr, I. E.	This is a proof of principle / feasibility study aiming to evaluate the effect of nebulised unfractionated heparin on procoagulant markers related to acute respiratory distress syndrome in patients invasively ventilated for Covid 19 lung disease	http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-003349-12-IE	Ongoing studies
51	Euctr, I. E.	A Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic	http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002190-10-IE	Ongoing studies
52	Euctr, I. T.	Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design	http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001921-30-IT	Ongoing studies

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
53	Euctr, S. E.	A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatment. The Immunomodulation-CoV Assessment (ImmCoVA) study	http://www.who.int/trialsearch/Trial2.aspx?trialID=EUCTR2020-001748-24-SE	Ongoing studies
54	Eviskov Ye, M.; Baykova, O. A.; Vechorko, V. I.	Analysis of the frequency of diseases of the cardiovascular system as an unfavorable premorbid background for the development of COVID-19, as well as the frequency of acute cardiovascular events during the period of hospitalization. [Russian]	http://dx.doi.org/10.17116/profmed20202308130	Other than English or Korean
55	Fattorutto, M.; Bouckaert, Y.; Brauner, J.; Franck, S.; Bouton, F.; Heuse, D.; Bouckaert, C.; Bruyneel, A.	Pragmatic study of a thromboprolylaxis algorithm in critically ill patients with SARS-COV-2 infection	10.1007/s11239-021-02514-3	Not intervention
56	Fei, M.; Tong, F.; Tao, X.; Wang, J.	Value of neutrophil-to-lymphocyte ratio in the classification diagnosis of Coronavirus disease 2019. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn121430-20200413-00506	Other than English or Korean
57	Fernandez-Capitan, C.; Barba, R.; Diaz-Pedroche, M. D. C.; Siguenza, P.; Demelo-Rodriguez, P.; Siniscalchi, C.; Pedrajas, J. M.; Farfan-Sedano, A. I.; Olivera, P. E.; Gomez-Cuervo, C.; Ilamas, P.; Villares, P.; Sanchez, O.; Lopez-Reyes, R.; Catella, J.; Bikkeli, B.; Weinberg, I.; Tafur, A. J.; Jimenez, D.; Montreal, M.	Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19	http://dx.doi.org/10.1055/s-0040-1718402	Not comparator
58	Fournier, M.; Faille, D.; Dossier, A.; Mageau, A.; Nicaise Roland, P.; Aizenberg, N.; Borie, R.; Bouadma, L.; Bunej, V.; Castier, Y.; Choquet, C.; Crestani, B.; Daugas, E.; Deconinck, L.; Descamps, D.; Descamps, V.; Dieude, P.; Ducrocq, G.; Faucher, N.; Goulenok, T.; Guidoux, C.; Khalil, A.; Lavallee, P.; Lescur, F. X.; Lortat-Jacob, B.; Mal, H.; Mutoon, P.; Pellenc, Q.; Steg, P. G.; Taille, C.; Timsit, J. F.; Yazdanpanah, Y.; Papo, T.; Sacre, K.	Arterial Thrombotic Events in Adult Inpatients With COVID-19	http://dx.doi.org/10.1016/j.jmayocp.2020.11.018	Not outcome
59	Frohlich, G. M.; Jeschke, E.; Eichler, U.; Thiele, H.; Alhariri, L.; Reinhaller, M.; Kastrati, A.; Leistner, D. M.; Skurk, C.; Landmesser, U.; Gunster, C.	Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany	http://dx.doi.org/10.1007/s00392-020-01783-x	Not outcome
60	Fumeaux, T.	[Not Available]	Rev Med Suisse 2021, 17(741):1098.	Other than English or Korean
61	Garcia Vallejo, O.; Frias Vargas, M.; Gil Gil, I.; Vazquez Gomez, N.; Piera Carbonell, A.; Peiro Morant, J.	Knowledge of thromboprolylaxis-COVID-19 in healthcare professionals in Spain. [Spanish]	http://dx.doi.org/10.1016/j.j-semerg.2021.01.002	Other than English or Korean
62	Gil-Rodrigo, A.; Miro, O.; Piner, P.; Burillo-Putze, G.; Jimenez, S.; Martin, A.; Martin-Sanchez, F. J.; Jacob, J.; Guardiola, J. M.; Garcia-Lamberechts, E. J.; Espinosa, B.; Martin Mojarro, E.; Gonzalez Tejera, M.; Serrano, L.; Aguera, C.; Soy, E.; Llauger, L.; Juan, M. A.; Palau, A.; Del Arco, C.; Rodriguez Miranda, B.; Maza Vera, M. T.; Martin Quiros, A.; Tejada de los Santos, L.; Ruiz de Lobera, N.; Iglesias Vela, M.; Torres Garate, R.; Alquezar-Arbe, A.; Gonzalez Del Castillo, J.; Llorens, P.	Analysis of clinical characteristics and outcomes in patients with covid-19 based on a series of 1000 patients treated in spanish emergency departments. [Spanish]	Emergencias 2020, 32(4):233-241.	Other than English or Korean
63	Gong, X.; Ye, Z. Q.; Zhang, W.; Yu, G.; Ruan, Q. F.; Xie, W. G.	[Changes in serum osteoprotegerin/receptor activator of nuclear factor- B ligand and related indexes of calcium and phosphorus in the early stage of severe burn patients]	10.3760/cma.j.cn501120-20190616-00272	Other than English or Korean

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
64	Gusev, D. A.; Vashukova, M. A.; Feduniak, I. P.; Musatov, V. B.; Kapatsyna, V. A.	Experience with the use of recombinant humanized monoclonal antibodies to the human receptor for interleukin-6 in patients with COVID-19. [Russian]	http://dx.doi.org/10.22625/2072-6732-2020-12-3-28-33	Other than English or Korean
65	Hai-Chao, L.; Long, L.; Cong-Zheng, M.; Rui-Juan, X.; Fang-Oi, Z.; Zhen-Hong, H.; Qing, S.	Analyses of the clinical features of 13 corona virus disease 2019 non-survivors. [Chinese]	http://dx.doi.org/10.11855/j.issn.0577-7402.2020.05.03	Other than English or Korean
66	Halaby, R.; Cuker, A.; Yui, J.; Matthews, A.; Ishaaya, E.; Traxler, E.; Domenico, C.; Cooper, T.; Tierney, A.; Niami, P.; van der Rijst, N.; Adusumalli, S.; Gutsche, J.; Giri, J.; Pugliese, S.; Hecht, T. E. H.; Pishko, A. M.; Hanisch, V.	Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study	10.1111/jth.15310	Not outcome
67	Harrison, R. F.; Forte, K.; Buscher, M. G., Jr.; Chess, A.; Patel, A.; Moylan, T.; Mize, C. H.; Werdmann, M.; Ferrigno, R.	COVID-19: The role of intensive care. [German]	http://dx.doi.org/10.1515/pubhef-2020-0128	Other than English or Korean
68	He, J.; Cheng, G.; Xu, W.; Zhang, L.; Zeng, Z.	The Association of Preinfection Daily Oral Anticoagulation Use and All-Cause in Hospital Mortality From Novel Coronavirus 2019 at 21 Days: A Retrospective Cohort Study	10.1097/jcc.0000000000000324	Not outcome
69	Huang, Z.; Xu, S.; Chen, J.; Wei, Q.; Lin, L.; Ye, X.; Xue, D.	Diagnosis and treatment of an elderly patient with secondary cerebral infarction caused by COVID-19. [Chinese]	http://dx.doi.org/10.12122/j.issn.1673-4254.2020.03.10	Other than English or Korean
70	He, J.; Cheng, G.; Xu, W.; Zhang, L.; Zeng, Z.	[Diagnosis and treatment of an elderly patient with secondary cerebral infarction caused by COVID-19]	10.12122/j.issn.1673-4254.2020.03.10	Other than English or Korean
71	Hong, M.; Wei, W.; Song, S.	Study of activated protein C resistance (APC-R) and FV Leiden in healthy blood donors and patients with thrombosis. [Chinese]	Zhonghua xueyexue zazhi 1998, 19(9):455-457.	Other than English or Korean
72	Huang, Z.; Xu, S.; Chen, J.; Wei, Q.; Lin, L.; Ye, X.; Xue, D.	Predictive value of laboratory tests on severity of newly hospitalized patients with COVID-19. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn114452-20200304-00174	Other than English or Korean
73	Iaccarino, G.; Grassi, G.; Borghi, C.; Grassi, D.; Mancusi, C.; Muresan, M. L.; Salvetti, M.; Volpe, M.; Ferri, C.	Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients	10.3389/fcvm.2021.633878	Not intervention
74	Ignacio-Ibarra, G.; Garcia-Lee, M. T.; Gonzalez-avila, A. I.; Garcia-Chavez, J.; Guzman-Chores, L.; Ledesma-De la Cruz, C.; Lugo-Garcia, Y.; Juarez-Lara, J.; Garcia-Vazquez, M.; Madera-Maldonado, C. E.; Ramos-Penafiel, C. O.; Majluf-Cruz, A.	A proposal for the management of covid-19-induced coagulopathy in adults. [Spanish]	http://dx.doi.org/10.24875/GMM.20000930	Other than English or Korean
75	Investigators, Inspiration; Sadehipour, P.; Talasaz, A. H.; Rashidi, F.; Sharif-Kashani, B.; Beigmohammadi, M. T.; Farrokhpour, M.; Sezavar, S. H.; Payandemehr, P.; Dabbagh, A.; Moghadam, K. G.; Jarmalkhani, S.; Khalili, H.; Yadollahzadeh, M.; Riahi, T.; Rezaeifar, P.; Tahamtan, O.; Matin, S.; Abedini, A.; Lookzadeh, S.; Rahmani, H.; Zoghi, E.; Mohammadi, K.; Abri, H.; Tabrizi, S.; Mousavian, S. M.; Shahmirzaei, S.; Bakhtshandeh, H.; Amin, A.; Rafiee, F.; Baghzadeh, E.; Mohebbi, B.; Parhizgar, S. E.; Aliannejad, R.; Eslami, V.; Kassefzadeh, A.; Kakavand, H.; Hosseini, S. H.; Shafaghi, S.; Ghazi, S. F.; Najafi, A.; Jimenez, D.; Gupta, A.; Madhavan, M. V.; Sethi, S. A.; Parikh, S. A.; Monreal, M.; Hadavand, N.; Hajjighasemi, A.; Maleki, M.; Sadeghian, S.; Piazza, G.; Kirtane, A. J.; Van Tassel, B. W.; Dobeish, P. P.; Stone, G. W.; Lip, G. Y. H.; Krumholz, H. M.; Goldhaber, S. Z.; Bikdeli, B.	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic	https://dx.doi.org/10.1001/jama.2021.4152	Duplication

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
76	Ionescu, F.; Grasso-Knight, G.; Castillo, E.; Naeem, E.; Petrescu, I.; Imam, Z.; Patel, V. K.; Narasimhan, M.; Nair, G. B.	Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort	http://dx.doi.org/10.1055/s-0040-1716721	Not intervention
77	Irc20091012002582N,	Effect of hemoperfusion on short term outcome of critically ill COVID-19	http://www.who.int/trialsearch/Trial2.aspx?trialID=IRCT20091012002582N22	Ongoing studies
78	Irc20151227025726N,	Pentaglobin effect in critically ill patients with COVID-19	http://www.who.int/trialsearch/Trial2.aspx?trialID=IRCT20151227025726N18	Ongoing studies
79	Irc20170809035597N,	Efficacy and safety of pentoxifylline in treatment and recovery of patients with COVID-19	http://www.who.int/trialsearch/Trial2.aspx?trialID=IRCT20170809035597N2	Ongoing studies
80	Isrctn,	A clinical trial to evaluate the effects of inhaled nitric oxide gas among COVID-19 patients with pneumonia	http://www.who.int/trialsearch/Trial2.aspx?trialID=ISRCTN16806663	Ongoing studies
81	Isrctn,	Understanding how COVID-19 leads to respiratory failure in COVID-19 positive patients	http://www.who.int/trialsearch/Trial2.aspx?trialID=ISRCTN14212905	Ongoing studies
82	Istvan, Z.; Aniko, S.; Barna, B.; Krisztian, T.; Laszlo, K.; Zsuzsanna, S.; Janos, F.	Procoagulation, hypercoagulation and fibrinolytic "shut down" detected with ClotPro viscoelastic tests in COVID-19 patients. [Hungarian]	http://dx.doi.org/10.1556/650.2020.31870	Other than English or Korean
83	Jonmarker, S.; Hollenberg, J.; Dahlberg, M.; Stackelberg, O.; Litorelli, J.; Everhov, H.; J rnbert-Pettersson, H.; S derberg, M.; Grip, J.; Schandl, A.; G nther, M.; Cronhjort, M.	Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients	10.1186/s13054-020-03375-7	Duplication
84	Karnalov, A. A.; Mareev, V. Yu.; Orlova Ia, A.	Conceptual approaches to finding effective treatment for a new coronavirus infection at different stages. [Russian]	http://dx.doi.org/10.15690/vramn1402	Other than English or Korean
85	Kaptein, F. H. J.; Stals, M. A. M.; Huisman, M. V.; Kloek, F. A.	Prophylaxis and treatment of COVID-19 related venous thromboembolism	10.1080/00325481.2021.1891788	Not RCTs or observational studies without control group
86	Karakoc, Z. C.; Pinarbasi-Simsek, B.; Asil, R.; Dodurgali, R.; Caliskaner, E.; Ozsari, A.; Tugrul, S.; Ece, F.	First wave in COVID-19 pandemic: A single center experience. [Turkish]	http://dx.doi.org/10.5152/kd.2020.47	Other than English or Korean
87	Karashahin, O.; Tosun Tasar, P.; Kerget, B.; Binici, D. N.; Karasahin, E. F.; Sevinc, C.; Serin, B. N.; Albayrak, A.	Prognostic factors of COVID-19 infection in older patients. [Turkish]	http://dx.doi.org/10.5578/FLORA.20219804	Other than English or Korean
88	Kartsios, C.; Lokare, A.; Osman, H.; Perrin, D.; Razaq, S.; Ayub, N.; Daddar, B.; Fair, S.	Diagnosis, management, and outcomes of venous thromboembolism in COVID-19 positive patients: a role for direct anticoagulants?	10.1007/s11239-020-02257-7	Not RCTs or observational studies without control group
89	Khizroeva, J. Kh.; Makatsariya, A. D.; Bitsadze, V. O.; Tret'yakova, M. V.; Slukhanchuk, E. V.; Elalamy, I.; Gris, J. C.; Radetskaya, L. S.; Makatsariya, N. A.; Sulina, Y. Yu.; Tsibizova, V. I.; Shkoda, A. S.; Blinov, D. V.	Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers. [Russian]	http://dx.doi.org/10.17749/2313-7347.141	Other than English or Korean
90	Kollias, A.; Kyriakoulis, K. G.; Lagou, S.; Kontopantelis, E.; Stergiou, G. S.; Syrigos, K.	Venous thromboembolism in COVID-19: A systematic review and meta-analysis	10.1177/1358863x21995566	Not comparator

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
91	Kotenko, O. N.; Artyukhina, L. Yu; Frolova, N. F.; Stolyarevich, E. S.	Clinical course and approaches to therapy in kidney transplant recipients with the novel covid-19 disease. [Russian]	http://dx.doi.org/10.15825/1995-1191-2020-4-69-74	Other than English or Korean
92	Kuznik, B. I.; Sturov, V. G.	Features of the course of the new coronavirus infection (Sars-cov-2) in children. [Russian]	http://dx.doi.org/10.24110/0031-403X-2020-99-6-199-208	Other than English or Korean
93	Li, C. X.; Wu, B.; Luo, F.; Zhang, N.	Clinical Study and CT Findings of a Familial Cluster of Pneumonia with Coronavirus Disease 2019 (COVID-19). [Chinese]	http://dx.doi.org/10.12182/20200360107	Other than English or Korean
94	Li, C. X.; Wu, B.; Luo, F.; Zhang, N.	[Clinical Study and CT Findings of a Familial Cluster of Pneumonia with Coronavirus Disease 2019 (COVID-19)]	10.12182/20200360107	Other than English or Korean
95	Li, T.; Wang, X.; Zhuang, X.; Wang, H.; Li, A.; Huang, L.; Zhang, X.; Xue, Y.; Wei, F.; Ma, C.	Baseline characteristics and changes of biomarkers in disease course predict prognosis of patients with COVID-19	https://dx.doi.org/10.1007/s11739-020-02560-4	Not intervention
96	Li, W.; Xu, Z.; Xiang, H.; Zhang, C.; Guo, Y.; Xiong, J.	Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status	10.18632/aging.202769	Not intervention
97	Lin, M.; Huang, Z.; Yu, B.	Serum biochemical markers for early prediction of severity of acute pancreatitis. [Chinese]	http://dx.doi.org/10.3969/j.issn.1008-7125.2015.08.007	Other than English or Korean
98	Linnemann, B.; Bauersachs, R.; Grebe, M.; Klamroth, R.; M Iler, O.; Schellong, S.; Lichtenberg, M.	Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA)	10.1024/0301-1526/a000885	Not intervention
99	Liu, J.; Zhou, Y.; Wang, M.; Liu, Y.; Du, H.; Wang, T.; Zhang, L.; Chen, Y.; Chen, D.	Application of continuous renal replacement therapy in coronavirus disease 2019. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn121430-20200508-00369	Other than English or Korean
100	Liu, J.; Zhou, Y.; Wang, M.; Liu, Y.; Du, H.; Wang, T.; Zhang, L.; Chen, Y.; Chen, D.	[Application of continuous renal replacement therapy in coronavirus disease 2019]	10.3760/cma.j.cn121430-20200508-00369	Other than English or Korean
101	Liu, W.; Mei, J.; Pan, X.; Guo, Z.; Duan, Z.; Ni, H.; Tang, K.; Zhu, M.; Wan, X.	Effects on prognosis of endovascular treatment beyond time windows in selected patients with acute ischemic stroke and hyperintense vessels sign on fluid-attenuated inversion recovery imaging. [Chinese]	http://dx.doi.org/10.3969/j.issn.1672-5921.2020.07.003	Other than English or Korean
102	Liu, Y.; Han, D. C.; Hu, Y. L.; Chen, L. M.; Li, J. C.; Su, Y. W.; Hu, C. X.	[Diagnosis and treatment of five neonatal cerebral venous sinus thrombosis]	10.3760/cma.j.issn.0578-1310.2018.10.009	Other than English or Korean
103	Llanes, O. M. A.	Sickle cell disease and covid-19: Microvascular alterations and inflammation. [Spanish]	Revista Cubana de Hematología, Inmunología y Hemoterapia 2020, 36(special issue):1-20.	Other than English or Korean
104	Lozano, Y.; Palacios, E. V.	Factors associated with the hospitalization of COVID-19 patients in a clinic's intensive care unit in 2020. [Spanish]	http://dx.doi.org/10.24265/HORIZMED.2021.V21N1.09	Other than English or Korean
105	Lynggaard, S. E.; Nygaard, L.; Overgaard, E. K.	Forhøjet D-dimer og karakteristiske billeddiagnostiske fund hos patient med COVID-19. [Danish]	Ugeskrift for læger 2020, 182(24).	Other than English or Korean
106	Mai, V.; Tan, B. K.; Mainbourg, S.; Potus, F.; Cuucherat, M.; Lega, J. C.; Provencher, S.	Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis	10.1016/j.vph.2021.106882	Not intervention

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
107	Makatsariya, A. D.; Grigorieva, K. N.; Mingalimov, M. A.; Bitsadze, V. O.; Khizroeva, J. Kh; Tretyakova, M. V.; Elalamy, I.; Shkoda, A. S.; Nemirovskiy, V. B.; Blinov, D. V.; Mitryuk, D. V.	Coronavirus disease (COVID-19) and disseminated intravascular coagulation. [Russian]	http://dx.doi.org/10.17749/2313-7347.132	Other than English or Korean
108	Mansory, E. M.; Srigunapalan, S.; Lazo-Langner, A.	Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis	10.1055/s-0041-1730967	Not intervention
109	Mariann, B.; Akos, F.; Istvan, L.; Tamas, V.; Csilla, M.; Bela, F.; Gyorgy, K.	Organ replacement therapy and life-supporting treatment modalities in critically ill COVID-19 patients [Hungarian]	http://dx.doi.org/10.1556/650.2020.31813	Other than English or Korean
110	Markelov, M. I.; Beznoshchenko, O. S.; Ivanets, T. Y.; Pyregov, A. V.; Esayan, R. M.; Gavrilova, T. Y.; Krechetova, L. V.	Plasma hemostatic system in patients with the novel coronavirus disease 2019 (COVID-19). [Russian]	http://dx.doi.org/10.18565/aig.2020.9.138-144	Other than English or Korean
111	Martini, N.; Piccinni, C.; Pedrini, A.; Maggioni, A.	[CoVID-19 and chronic diseases: current knowledge, future steps and the MaCroScopio project.]	10.1701/3347.33180	Other than English or Korean
112	Mendoza-Ticona, A.; Mesias, G. V.; Aquehua, A. O.; Chacaliza, B. C.; Loli, G. G.; Cruz, C. A.; Rivero Vallenas, J. P.	Clinical classification and early therapy for COVID-19. Cases reported from Hospital de Emergencias Villa El Salvador, Lima-Peru. [Spanish]	http://dx.doi.org/10.35663/amp.2020.372.968	Other than English or Korean
113	Mingchao, Z.; Ya, Z.; Feibo, G.; Jue, Z.; Weiping, L.; Wei, H.	Clinical and laboratory characteristics of 215 cases of coronavirus disease 2019 with different prognosis. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn121430-20200824-00590	Other than English or Korean
114	Mitra, S.; Ling, R. R.; Yang, I. X.; Poon, W. H.; Tan, C. S.; Monagle, P.; Maclaren, G.; Ramanathan, K.	Severe COVID-19 and coagulopathy: A systematic review and meta-analysis	http://dx.doi.org/10.47102/annals-acadmedsg.2020420	Not intervention
115	Moore, H. B.; Barrett, C. D.; Moore, E. E.; Jhurjunhwal, R.; McIntyre, R. C.; Moore, P. K.; Wang, J.; Hajizadeh, N.; Taimor, D. S.; Sauaia, A.; Yaffe, M. B.	Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2(COVID-19): Study design of the phase IIa STARS trial	http://dx.doi.org/10.1002/rth2.12395	Not population
116	Mosconi, G.; Spazzoli, A.; Bruno, P. F.; Angelini, M. L.; Cristino, S.; Liffrieri, M. F.; Americo, C.; De Fabritiis, M.; Ambri, K.; Dirani, G.; Semprini, S.; Sambri, V.; Zambianchi, L.	Resilience in COVID-19 times: general considerations on the recovery of a 93-year-old patient on haemodialysis treatment. [Italian]	G Ital Nefrol 2020, 37(5).	Other than English or Korean
117	Mosconi, G.; Spazzoli, A.; Bruno, P. F.; Angelini, M. L.; Cristino, S.; Liffrieri, M. F.; Americo, C.; De Fabritiis, M.; Ambri, K.; Dirani, G.; Semprini, S.; Sambri, V.; Zambianchi, L.	[Resilience in COVID-19 times: general considerations on the recovery of a 93-year-old patient on haemodialysis treatment]	G Ital Nefrol 2020, 37(5).	Other than English or Korean
118	Motta, J. K.; Ogunnaike, R. O.; Shah, R.; Stroever, S.; Cedeno, H. V.; Thapa, S. K.; Chronakos, J. J.; Jimenez, E. J.; Petrini, J.; Hegde, A.	Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in Coronavirus Disease 2019	10.1097/ccce.0000000000000309	Not population
119	Muhlberger, V.; Kaltenbach, L.; Bates, K.; Jeger, R.; Ulmer, H.	Cardiac catheterization, coronary angiography (CA) and percutaneous coronary interventions (PCI) in Austria during the year 2019 (registry data including audit 2020. [German]	Journal fur Kardiologie 2021, 28(1-2):22-27.	Other than English or Korean
120	Munoz-Rivas N.; Abad-Motos, A.; Mestre-Gomez, B.; Sierra-Hidalgo, F.; Cortina-Camarero, C.; Lorente-Ramos, R. M.; Torres-Rubio, P.; Arranz-Garcia, P.; Franco-Moreno, A. I.; Gomez-Mariscal, E.; Mauleon-Fernandez, C.; Alonso-Garcia, S.; Rogado, J.; Saez-Vaquero, T.; Such-Diaz, A.; Ryan, P.; Moya-Mateo, E.; Martin-Navarro, J. A.; Hernandez-Rivas, J. A.; Torres-Macho, J.; Churrua, J.	Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study	http://dx.doi.org/10.1016/j.thromres.2020.12.024	Not population

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
121	Myasnikov, A. L.; Berns, S. A.; Talyzin, P. A.; Ershov, F. I.	[Interferon gamma in the treatment of patients with moderate COVID- 19]	10.36233/0507-4088-24	Other than English or Korean
122	Nadeem, R.; Thomas, S. J.; Fathima, Z.; Palathinkal, A. S.; Alkilani, Y. E.; Dejan, E. A.; Darwish, I. M. I.; Alsubousi, A. A.; Backour, A. M.; Kandeel, H.; Omar, M.; Kewan, Hfy; Makhlof, M. E.; Kotgire, A. B.	Pattern of anticoagulation prescription for patients with Covid-19 acute respiratory distress syndrome admitted to ICU. Does it impact outcome?	10.1016/j.hrtlng.2020.10.009	Not intervention
123	Nasonov, E. L.; Beketova, T. V.; Reshetnyak, T. M.; Lila, A. M.; Ananieva, L. P.; Lisitsyna, T. A.; Soloviev, S. K.	Coronavirus disease 2019 (covid-19) and immune-mediated inflammatory rheumatic diseases: At the crossroads of thromboinflammation and autoimmunity. [Russian]	http://dx.doi.org/10.47360/1995-4484-2020-353-367	Other than English or Korean
124	Nazli, A.; Emececi, A. N.; Eren Kutlusoylu, O. O.; Omeroglu Simsek, G.; Ozgen Alpaydin, A.; Bayram, B.; Appak, O.; Unal, B.; Yapar, N.; Avkan Oguz, V.	Mortality and reinfection rates of the patients with mild COVID-19 at the sixth month after the infection. [Turkish]	http://dx.doi.org/10.5578/FLORA.20219806	Other than English or Korean
125	Nct,	Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19	https://clinicaltrials.gov/show/NCT04808895	Ongoing studies
126	Nct,	Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-III COVID-19 Patients	https://clinicaltrials.gov/show/NCT04457609	Ongoing studies
127	Nct,	Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)	https://clinicaltrials.gov/show/NCT04406389	Ongoing studies
128	Nct,	Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial	https://clinicaltrials.gov/show/NCT04445935	Ongoing studies
129	Nct,	ANTIcoagulation in Severe COVID- 19 Patients	https://clinicaltrials.gov/show/NCT04808882	Ongoing studies
130	Nct,	Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4)	https://clinicaltrials.gov/show/NCT04505774	Ongoing studies
131	Nct,	Baricitinib Compared to Standard Therapy in Patients With COVID-19	https://clinicaltrials.gov/show/NCT04393051	Ongoing studies
132	Nct,	Chinese Medicine for Patients With LCOVID-19 Symptoms	https://clinicaltrials.gov/show/NCT04924881	Ongoing studies
133	Nct,	Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection: a Randomized Clinical Trial	https://clinicaltrials.gov/show/NCT04600141	Ongoing studies
134	Nct,	Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection	https://clinicaltrials.gov/show/NCT04523831	Ongoing studies
135	Nct,	Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19	https://clinicaltrials.gov/show/NCT04420299	Ongoing studies
136	Nct,	Coagulopathy of COVID-19: a Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care	https://clinicaltrials.gov/show/NCT04362085	Ongoing studies
137	Nct,	Comparison of Two Different Doses of Bemiparin in COVID-19	https://clinicaltrials.gov/show/NCT04604327	Ongoing studies

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
138	Nct,	Convalescent Plasma as a Possible Treatment for COVID-19	https://clinicaltrials.gov/show/NCT04442191	Ongoing studies
139	Nct,	Coronavirus (COVID-19) ACEI/ARB Investigation	https://clinicaltrials.gov/show/NCT04330300	Ongoing studies
140	Nct,	COVID-19 Antithrombotic Rivaroxaban Evaluation	https://clinicaltrials.gov/show/NCT04757857	Ongoing studies
141	Nct,	COVID-19 Thrombosis Prevention Trials: post-hospital Thromboprophylaxis	https://clinicaltrials.gov/show/NCT04650087	Ongoing studies
142	Nct,	Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure	https://clinicaltrials.gov/show/NCT04389840	Ongoing studies
143	Nct,	Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19	https://clinicaltrials.gov/show/NCT04416048	Ongoing studies
144	Nct,	Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection	https://clinicaltrials.gov/show/NCT04508439	Ongoing studies
145	Nct,	Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients	https://clinicaltrials.gov/show/NCT04421404	Ongoing studies
146	Nct,	Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic	https://clinicaltrials.gov/show/NCT04668469	Ongoing studies
147	Nct,	Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)	https://clinicaltrials.gov/show/NCT04352400	Ongoing studies
148	Nct,	Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection	https://clinicaltrials.gov/show/NCT04854941	Ongoing studies
149	Nct,	Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (budilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS	https://clinicaltrials.gov/show/NCT04429555	Ongoing studies
150	Nct,	Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19	https://clinicaltrials.gov/show/NCT04646655	Ongoing studies
151	Nct,	Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19	https://clinicaltrials.gov/show/NCT04400799	Ongoing studies
152	Nct,	Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment	https://clinicaltrials.gov/show/NCT04673214	Ongoing studies
153	Nct,	Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19	https://clinicaltrials.gov/show/NCT04376788	Ongoing studies
154	Nct,	Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: a Phase 2a Clinical Trial	https://clinicaltrials.gov/show/NCT04357730	Ongoing studies
155	Nct,	Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial	https://clinicaltrials.gov/show/NCT04394377	Ongoing studies
156	Nct,	Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients	https://clinicaltrials.gov/show/NCT04401293	Ongoing studies

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
157	Nct,	Hamburg Edoxaban for Anticoagulation in COVID-19 Study	https://clinicaltrials.gov/show/NCT04542408	Ongoing studies
158	Nct,	Hesperidin and Diosmin for Treatment of COVID-19	https://clinicaltrials.gov/show/NCT04452799	Ongoing studies
159	Nct,	High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy	https://clinicaltrials.gov/show/NCT04408235	Ongoing studies
160	Nct,	Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19	https://clinicaltrials.gov/show/NCT04361318	Ongoing studies
161	Nct,	Hyperimmune Plasma in Patients With COVID-19 Severe Infection	https://clinicaltrials.gov/show/NCT04385043	Ongoing studies
162	Nct,	Impact of Colchicine and Low-dose Naltrexone on COVID-19	https://clinicaltrials.gov/show/NCT04756128	Ongoing studies
163	Nct,	Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)	https://clinicaltrials.gov/show/NCT04453371	Ongoing studies
164	Nct,	Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19	https://clinicaltrials.gov/show/NCT04367831	Ongoing studies
165	Nct,	Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19	https://clinicaltrials.gov/show/NCT04486508	Ongoing studies
166	Nct,	Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients	https://clinicaltrials.gov/show/NCT04794088	Ongoing studies
167	Nct,	I-SPY COVID-19 TRIAL: an Adaptive Platform Trial for Critically Ill Patients	https://clinicaltrials.gov/show/NCT04488081	Ongoing studies
168	Nct,	Ivermectin and Nitazoxanide Combination Therapy for COVID-19	https://clinicaltrials.gov/show/NCT04360356	Ongoing studies
169	Nct,	Low-Dose Tenecteplase in Covid-19	https://clinicaltrials.gov/show/NCT04558125	Ongoing studies
170	Nct,	Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism	https://clinicaltrials.gov/show/NCT04558125	Ongoing studies
171	Nct,	LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)	https://clinicaltrials.gov/show/NCT04402957	Ongoing studies
172	Nct,	Managing Endothelial Dysfunction in COVID-19 : a Randomized Controlled Trial at LAUMC	https://clinicaltrials.gov/show/NCT04631536	Ongoing studies
173	Nct,	Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH	https://clinicaltrials.gov/show/NCT04813471	Ongoing studies
174	Nct,	Mesenchymal Stem Cell Infusion for COVID-19 Infection	https://clinicaltrials.gov/show/NCT04444271	Ongoing studies

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
175	Nct,	Nebulised Heparin in Patients With Severe COVID-19	https://clinicaltrials.gov/show/NCT04545541	Ongoing studies
176	Nct,	Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury	https://clinicaltrials.gov/show/NCT04511923	Ongoing studies
177	Nct,	Nebulised Heparin for the Treatment of COVID-19	https://clinicaltrials.gov/show/NCT04723563	Ongoing studies
178	Nct,	Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury	https://clinicaltrials.gov/show/NCT04397510	Ongoing studies
179	Nct,	Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19	https://clinicaltrials.gov/show/NCT04530578	Ongoing studies
180	Nct,	Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED	https://clinicaltrials.gov/show/NCT04338828	Ongoing studies
181	Nct,	Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19	https://clinicaltrials.gov/show/NCT04745442	Ongoing studies
182	Nct,	Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure	https://clinicaltrials.gov/show/NCT04634422	Ongoing studies
183	Nct,	A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to COVID-19 Pandemic	https://clinicaltrials.gov/show/NCT04444700	Ongoing studies
184	Nct,	Prasugrel in Severe COVID-19 Pneumonia	https://clinicaltrials.gov/show/NCT04445623	Ongoing studies
185	Nct,	Preventing COVID-19 Complications With Low- and High-dose Anticoagulation	https://clinicaltrials.gov/show/NCT04345848	Ongoing studies
186	Nct,	Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial	https://clinicaltrials.gov/show/NCT04409834	Ongoing studies
187	Nct,	Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers	https://clinicaltrials.gov/show/NCT04461379	Ongoing studies
188	Nct,	Protective Effect of Aspirin on COVID-19 Patients	https://clinicaltrials.gov/show/NCT04365309	Ongoing studies
189	Nct,	Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19	https://clinicaltrials.gov/show/NCT04770740	Ongoing studies
190	Nct,	Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients	https://clinicaltrials.gov/show/NCT04768179	Ongoing studies
191	Nct,	Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19	https://clinicaltrials.gov/show/NCT04377997	Ongoing studies
192	Nct,	Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients	https://clinicaltrials.gov/show/NCT04869579	Ongoing studies

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
193	Nct,	Self-prone Positioning for Awake Non-intubated Patients With COVID-19	https://clinicaltrials.gov/show/NCT04760561	Ongoing studies
194	Nct,	Semaglutide to Reduce Myocardial Injury in PATients With COVID-19	https://clinicaltrials.gov/show/NCT04615871	Ongoing studies
195	Nct,	Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection	https://clinicaltrials.gov/show/NCT04528888	Ongoing studies
196	Nct,	Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19	https://clinicaltrials.gov/show/NCT04634799	Ongoing studies
197	Nct,	A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19	https://clinicaltrials.gov/show/NCT04640194	Ongoing studies
198	Nct,	Suloxide in the Treatment of Early Stages of COVID-19	https://clinicaltrials.gov/show/NCT04483830	Ongoing studies
199	Nct,	Tenecteplase in Patients With COVID-19	https://clinicaltrials.gov/show/NCT04505592	Ongoing studies
200	Nct,	Treating COVID-19 With Hydroxychloroquine (TEACH)	https://clinicaltrials.gov/show/NCT04369742	Ongoing studies
201	Nct,	Trial evaluating efficacy and safety of anticoagulation in patients with COVID-19 infection, nested in the corimmuno-19 cohort	https://clinicaltrials.gov/show/NCT04344756	Ongoing studies
202	Nct,	Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	https://clinicaltrials.gov/show/NCT04385836	Ongoing studies
203	N'Djessan J, J.; Gbassi, C.; Ekou, A.; Ehourman, E.; Toure, C.; Aman-Yaye, A.; Konin, C.; Anzouan-Kacou, J. B.	Severe pulmonary embolism revealing covid-19 infection: About a case and literature review. [French]	http://dx.doi.org/10.1684/stv.2020.1130	Other than English or Korean
204	Nl,	A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infections	http://www.who.int/trialsearch/Trial2.aspx?trialID=NL8633	Ongoing studies
205	Novikova, Y. Y.; Ovsyannikov, D. Yu; Glazyrina, A. A.; Zhdanova, O. I.; Zvereva, N. N.; Karpenko, M. A.; Kryshova, E. S.; Kurbanova, S. Kh; Rtishchev, A. Yu; Sayfullin, R. F.; Kharkin, A. V.; Shchederkina, I. O.; Bryksina, E. Yu; Bogdan, P. I.; Kolganova, N. I.; Sergeev, D. A.; Zorina, M. A.; Petryaykina, E. E.; Gorev, V. V.	Clinical, laboratory-instrumental characteristics, course and therapy of pediatric multisystem inflammatory syndrome associated with covid-19. [Russian]	http://dx.doi.org/10.24110/0031-403X-2020-99-6-73-83	Other than English or Korean
206	Oriol-Lopez, S. A.	Perioperative management of the patient with covid-19 coagulopathy. [Spanish]	http://dx.doi.org/10.35366/94938	Other than English or Korean
207	Ouyang, C. X.; Liu, J. Y.; Jin, B.	Endovascular covered stent graft exclusion and prosthetic vessel replacement for treatment of abdominal aortic aneurysm: Comparison of 1-year follow-up outcomes. [Chinese]	Journal of Clinical Rehabilitative Tissue Engineering Research 2007, 11(47):9608-9611.	Other than English or Korean
208	Papamitsou, T.; Lionta, Alpha; Mpouga, L.; Kawadas, D.; Aidoni, Z.; Sioga, Alpha	Covid-19: A short review of the therapeutic approaches and challenges faced by intensive care unit nurses. [Greek]	Archives of Hellenic Medicine 2021, 38(3):343-350.	Other than English or Korean

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
209	Paramo, J. A.	Coagulopathy and thrombosis: Similarities and differences among pathogenic coronaviruses. [Spanish]	http://dx.doi.org/10.23938/ASSN0885	Other than English or Korean
210	Pawlowski, C.; Venkatakrishnan, A. J.; Kirkup, C.; Berner, G.; Puranik, A.; O'Horo, J. C.; Badley, A. D.; Soundararajan, V.	Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients	10.1016/j.eclim.2021.100774	Not RCTs or observational studies without control group
211	Per,	RANDOMIZED PHASE IIA CLINICAL TRIAL TO COMPARE THE EFFICACY OF IVERMECTIN VERSUS PLACEBO TO OBTAIN NEGATIVE PCR RESULTS IN PATIENTS WITH EARLY PHASE COVID-19	http://www.who.int/trialsearch/Trial2.aspx?trialid=PER-034-20	Ongoing studies
212	Perepu, U. S.; Chambers, I.; Wahab, A.; Ten Eyck, P.; Wu, C.; Dayal, S.; Sutamtwagul, G.; Bailey, S. R.; Rosenstein, L. J.; Lentz, S. R.	Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial	https://dx.doi.org/10.1111/jth.15450	Duplication
213	Peters, P.; Sprynger, M.; Lancellotti, P.; Oury, C.	Coagulopathies, thrombotic risk and anticoagulation in COVID-19. [French]	Rev Med Liege 2020, 75(S1):86-93.	Other than English or Korean
214	Peters, P.; Sprynger, M.; Lancellotti, P.; Oury, C.	[Coagulopathies, thrombotic risk and anticoagulation in COVID-19]	Rev Med Liege 2020, 75(S1):86-93.	Other than English or Korean
215	Picariello, C.; Caravita, S.; Vatrano, M.; Enea, I.; Roncon, L.; de Tommasi, E.; Imbalzano, E.; Garascia, A.; Manes, M. T.; Misuraca, L.; Urbinati, S.; Colivicchi, F.; Gulizia, M. M.; Gabrielli, D.	ANMCO Position paper: Pulmonary circulation diseases and COVID-19. [Italian]	http://dx.doi.org/10.1714/j3405.33888	Other than English or Korean
216	Pinzon, D.; Baumgarten, D.; Galetke, W.	39-Year-Old Woman with Severe COVID-19 Pneumonia: Successful Weaning after Septic Shock and Forefoot Amputation after Microvascular Complications. [German]	http://dx.doi.org/10.1055/a-1362-4028	Other than English or Korean
217	Pinzon, D.; Baumgarten, D.; Galetke, W.	[39-Year-Old Woman with Severe COVID-19 Pneumonia: Successful Weaning after Septic Shock and Forefoot Amputation after Microvascular Complications]	10.1055/a-1362-4028	Other than English or Korean
218	Pordany, B.; Herczeg, G.; Miklos, M.	[Colon cancer during the coronavirus pandemic ??recovery from COVID-19 pneumonia of an elderly woman with multiple co-morbidities]	10.1556/650.2020.31866	Other than English or Korean
219	Poulakou, G.; Dimakos, E.; Kollias, A.; Kyriakoulis, K. G.; Rapti, V.; Trontzas, I.; Thanos, C.; Abdelrasoul, M.; Vantana, T.; Leontis, K.; Kakalou, E.; Argyraki, K.; Baraboutis, I.; Michelakis, E.; Giarmarellos-Bourboulis, E.; Dimakou, K.; Tsoukalas, G.; Rapti, A.; Michelakis, E. D.; Syrigos, K. N.	Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study	10.21873/invivo.12305	Not comparator
220	Pozzi, M.; Giani, M.; Fumagalli, B.; Calabria, M.; Leni, D.; Segramora, V.; Bellani, G.; Foti, G.	Role of Complete Duplex Ultrasound to Diagnose Deep Vein Thrombosis in COVID-19 Critical Patients	http://dx.doi.org/10.1177/1544316720985812	Not intervention
221	Qing, L.; Jiu-Long, W.; Bo, Z.; Zhi-Qiang, X.; Shi-Fang, D.	Characteristics of myocardial injury in severe and critical coronavirus disease 2019 patients and its effect on prognosis. [Chinese]	http://dx.doi.org/10.16781/j.0258-879x.2020.06.0596	Other than English or Korean
222	Quezada-Feijoo, M.; Ramos, M.; Lozano-Montoya, I.; Toro, R.; Jaramillo-Hidalgo, J.; Fernandez de la Puente, E.; Garmendia, B.; Carrillo, P.; Cristofori, G.; Goni Roson, S.; Ayala, R.; Sarro, M.; Gomez-Pavon, F. J.	Predictive factors of pulmonary embolism in older patients with sars-cov-2: The octa-covid-19 study	http://dx.doi.org/10.3390/jcm10132998	Not comparator

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
223	R. B. R. kf9p	Cov-Hep study : comparative study between different anti-coagulation strategies in continuous hemodialysis in COVID-19 patients	http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-45kf9p	Ongoing studies
224	R. B. R. rdhgm	The role of early dialysis in the evolution of patients with COVID19	http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-3rdhgm	Ongoing studies
225	R. B. R. z6v	Full versus prophylactic anticoagulation for the treatment of severe forms of Covid-19	http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-949z6v	Ongoing studies
226	Remy-Jardin, M.; Duthoit, L.; Perez, T.; Felloni, P.; Faivre, J. B.; Fry, S.; Bautin, N.; Chenivresse, C.; Remy, J.; Duhamel, A	Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: Dual-energy CT (DECT) angiographic study in 55 patients	http://dx.doi.org/10.1016/j.jecim.2021.100778	Not comparator
227	Rentsch, C. T.; Beckman, J. A.; Tomlinson, L.; Gellad, W. F.; Alcorn, C.; Kidwai-Khan, F.; Skanderson, M.; Brittain, E.; King, J. T., Jr.; Ho, Y. L.; Eden, S.; Kundu, S.; Lann, M. F.; Greevy, R. A., Jr.; Ho, P. M.; Heidenreich, P. A.; Jacobson, D. A.; Douglas, I. J.; Tate, J. P.; Evans, S. J. W.; Atkins, D.; Justice, A. C.; Freiberg, M. S.	Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study	10.1136/bmj.n311	Not outcome
228	Rentsch, C. T.; Beckman, J. A.; Tomlinson, L.; Gellad, W. F.; Alcorn, C.; Kidwai-Khan, F.; Skanderson, M.; Brittain, E.; King, J. T.; Ho, Y. L.; Eden, S.; Kundu, S.; Lann, M. F.; Greevy, R. A.; Ho, P. M.; Heidenreich, P. A.; Jacobson, D. A.; Douglas, I. J.; Tate, J. P.; Evans, S. J.; Atkins, D.; Justice, A. C.; Freiberg, M. S.	Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States	10.1101/2020.12.09.20246579	Not outcome
229	Rubina, K. A.; Sabitova, N. R.; Efimenko, A. Y.; Kalimina, N. I.; Akopyan, J. A.; Semina, E. V.	Proteolytic enzyme and adiponectin receptors as potential targets for COVID-19 therapy. [Russian]	http://dx.doi.org/10.15829/1728-8800-2021-2791	Other than English or Korean
230	Rui-Yong, C.; Yan-Chao, T.; Xiao-Ling, Z.; Yi, L.; Bu-Jun, L.; Xiao-Lan, T.; Chang-Bo, L.	Efficacy analysis of hyperbaric oxygen therapy in the treatment of severe coronavirus disease 2019 patients. [Chinese]	http://dx.doi.org/10.16781/j.0258-879x.2020.06.0604	Other than English or Korean
231	Russo, V.; Cardillo, G.; Viggiano, G. V.; Mangiacapra, S.; Cavalli, A.; Fontanella, A.; Agrusta, F.; Bellizzi, A.; Amitrano, M.; Iannuzzo, M.; Sacco, C.; Lodigiani, C.; Di Micco, P.	Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience	10.1097/jfc.0000000000000893	Not intervention
232	Ruzhentsova, T. A.; Khavkina, D. A.; Chukhlaev, P. V.; Garbuzov, A. A.; Ploskireva, A. A.	[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients]	10.36233/0507-4088-14	Other than English or Korean
233	Ruzhentsova, T. A.; Khavkina, D.; Chukhlaev, P. V.; Garbuzov, A. A.; Ploskireva, A. A.	Effect of anticoagulant therapy on the course of covid-19 in comorbid patients. [Russian]	http://dx.doi.org/10.36233/0507-4088-14	Other than English or Korean
234	Samaniego, F.; Conte, G.	SARS-CoV-2 infection as a thrombo-inflammatory endothelial disease. [Spanish]	http://dx.doi.org/10.4067/S0034-98872020001001467	Other than English or Korean
235	Samaniego, F.; Conte, G.	[SARS-CoV-2 infection as a thrombo-inflammatory endothelial disease]	10.4067/S0034-98872020001001467	Other than English or Korean
236	Sanchez Van Kammen, M.; Heldner, M. R.; Brodard, J.; Scutelnic, A.; Silvis, S.; Schroeder, V.; Kremer Hovinga, J. A.; Middeldorp, S.; Levi, M.; Hiltunen, S.; Lindgren, E.; Mansour, M.; Arauz, A.; Barboza, M. A.; Zuurbier, S. M.; Aguiar De Sousa, D.; Ferro, J. M.; Fischer, U.; Field, T. S.; Jood, K.; Tattisumak, T.; Putaala, J.; Arnold, M.; Coutinho, J. M.	Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients with Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic	http://dx.doi.org/10.1001/jama.2021.9889	Not intervention

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
237	Santoro, F.; Nunez-Gil, I. J.; Viana-Llamas, M. C.; Maroun Eid, C.; Romero, R.; Fernandez Rozas, I.; Aparisi, A.; Becerra-Munoz, V. M.; Garcia Aguado, M.; Huang, J.; Maltese, L.; Cerrato, E.; Alfonso-Rodriguez, E.; Castro Mejia, A. F.; Marin, F.; Raposeiras Roubin, S.; Pepe, M.; Moreno Munguia, V. H.; Feltes, G.; Navas, J. V.; Cortese, B.; Buzon, L.; Liebetrau, C.; Ramos-Martinez, R.; Fernandez-Ortiz, A.; Estrada, V.; Brunetti, N. D.	Anticoagulation Therapy in Patients with Coronavirus Disease 2019: Results from a Multicenter International Prospective Registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19])	http://dx.doi.org/10.1097/CCM.00000000000005010	Other than English or Korean
238	Scarduelli, C.; Inglesse, F.; Beccaria, M.; Specifico, F.; Garuti, M.; Pecoriello, A.; Cervi, G.; Greco, G.; Scarduelli, S.; Lucchini, G.; De Donno, G.; Borghi, C.	Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study	http://dx.doi.org/10.4081/monaldi.2021.1758	Not comparator
239	Schiaffino, S.; Giacomazzi, F.; Esseridou, A.; Cozzi, A.; Carriero, S.; Mazzaccaro, D. P.; Nano, G.; Di Leo, G.; Spagnolo, P.; Sardanelli, F.	Pulmonary thromboembolism in coronavirus disease 2019 patients undergoing thromboprophylaxis	10.1097/MD.00000000000024002	Not comparator
240	Schiavone, M.; Gasperetti, A.; Mancone, M.; Curnis, A.; Mascioli, G.; Mitacchione, G.; Busana, M.; Sabato, F.; Gobbi, C.; Antinori, S.; Galli, M.; Forleo, G. B.	Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience	10.1016/j.jicard.2020.09.001	Not RCTs or observational studies without control group
241	Shestakova, M. V.; Kononenko, I. V.; Kalmykova, Z. A.; Zheleznyakova, A. V.; Mokrysheva, N. G.	High level of glycoated hemoglobin (hba1c) in patients with covid-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus. [Russian]	http://dx.doi.org/10.14341/DM12702	Other than English or Korean
242	Shlyakhto, Y. V.; Arutyunov, G. P.; Belenkov, Y. N.; Tarlovskaya, E. I.; Konradi, A. O.; Panchenko, E. P.; Yavelov, I. S.; Tereshchenko, S. N.; Ardashchev, A. V.; Arutyunov, A. G.; Grigorieva, N. Y.; Dzhunusbekova, G. A.; Drapkina, O. M.; Koziolova, N. A.; Komarov, A. L.; Kropacheva, E. S.; Malchikova, S. V.; Mitkovskaya, N. P.; Orlova, Y. A.; Petrova, M. M.; Rebrov, A. P.; Siskian, H.; Skibitskiy, V. V.; Sugraliyev, A. B.; Fomin, I. V.; Chesnikova, A. I.; Snoposhnik, I.; Zhelyakov, E. G.; Kanorskiy, S. G.; Kolotsey, L. V.; Snezhitskiy, V. A.	[Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts' Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhythmology Association]	10.18087/cardio.2020.6.n1180	Other than English or Korean
243	Silvestri, C.; Di Stanete, S.; Bertuzzi, V.; Martello, M.; Palladino, M.; Grabocka, X.; Kulurianu, H.; Manenti, F.; Pizzolante, F.; Cardillo, A.; Francioso, A.; Paci Della Costanza, O.; Valentini, C.; Di Luca, M.	[SARS CoV-2 related disease features in a population of chronic hemodialysis patients]	G Ital Nefrol 2020, 37(6).	Other than English or Korean
244	Sosa-Garcia, J. O.; Gutierrez-Villasenor, A. O.; Garcia-Briones, A.; Romero-Gonzalez, J. P.; Juarez-Hernandez, E.; Gonzalez-Chon, O.	Experience in the management of severe COVID-19 patients in an intensive care unit. [Spanish]	http://dx.doi.org/10.24875/CIRU.20000675	Other than English or Korean
245	Spiegelberg, J. P.; van Gelder, Mmhj; Maas, M. L.; Hovens, M. M. C.; Esselink, A.; Dofferhoff, A. S. M.; Janssen, R.; van de Maat, J.; Janssen, N.; Blaauw, M.; Hassing, R. J.; van Apeldoorn, M.; Kerckhoffs, A.; Veerman, K.; Hoogerwerf, J.; Kramers, C.; Leentjens, J.	Prior use of therapeutic anticoagulation does not protect against COVID-19 related clinical outcomes in hospitalized patients: A propensity score-matched cohort study	10.1111/bcp.14877	Not population
246	Tang, Q.; Li, S.; Zhong, Y.; Li, C.; Liu, P.; Tian, X.; Jiang, Y.; Liu, W.; Sun, Z.; Guan, Q.	Relationship between myocardial injury, hypercoagulability and inflammatory markers in patients with COVID-19. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn114452-20200423-00424	Other than English or Korean
247	Tashchyan, O. V.; Mnatsakanyan, M. G.; Pogromov, A. P.; Kuprina, I. V.; Shurnskaya Yu, F.	Covid-19 in decompensated cirrhosis. [Russian]	http://dx.doi.org/10.15825/1995-1191-2020-4-197-201	Other than English or Korean
248	Tieleman, R. G.; Klok, F. A.; Belfroid, E.; Hoogervorst-Schilp, J.; Schalkers, I.; Jansen, C. W.; Siebelink, H. J.	Effect of anticoagulant therapy in COVID-19 patients	10.1007/s12471-021-01574-7	Not intervention

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
249	Tjonnfjord, E.; Overstad, S.; Aballi, S.; Ghanima, W.	[Thromboprophylaxis for patients with COVID-19 infection]	10.4045/ftdsskr.20.0603	Other than English or Korean
250	Toschi, V.	[Thrombosis and COVID-19 vaccine: much ado about nothing?]	10.1714/3612.35927	Other than English or Korean
251	Trang, T. N. T.; Gulpen, A. J. W.; van Duijnhoven, H. J. L. P.; Jacobs, C. J. G. M.	Prevention of underdosing of dalteparin against lung embolism: Dosing on anti-XA levels outcome in obese COVID-19 patient. [Dutch]	Pharmaceutisch Weekblad 2020,	Other than English or Korean
252	Trivi, M.; Lalor, N.; Spaletta, P.; Raffaelli, A.; Costabel, J.; Belardi, J.	[Acute myocardial infarction in patients recovering from COVID-19 pneumonia]	Medicina (B Aires) 2020, 80 Suppl 6:97-99.	Other than English or Korean
253	Tweit, L.; Enriquez, B.; Tennoe, B.; Warsza, B.; Garstad, L. J.; Weisshaar, M.; Aamodt, A. H.	[Cerebral venous thrombosis after COVID-19]	10.4045/ftdsskr.20.05663	Other than English or Korean
254	van der Linden, J.; Almskog, L.; Liliequist, A.; Grip, J.; Fux, T.; Rysz, S.; Agren, A.; Oldner, A.; Stahlberg, M.	Thromboembolism, Hypercoagulopathy, and Antiphospholipid Antibodies in Critically Ill Coronavirus Disease 2019 Patients: A Before and After Study of Enhanced Anticoagulation	10.1097/ccs.0000000000000308	Not intervention
255	Vandenbriele, C.; Gorog, D. A.	Screening for venous thromboembolism in patients with COVID-19	10.1007/s11239-021-02474-8	Not intervention
256	Vaughn, V. M.; Yost, M.; Abshire, C.; Flanders, S. A.; Pajje, D.; Grant, P.; Kaatz, S.; Kim, T.; Barnes, G. D.	Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19	10.1001/jamanetworkopen.2021.11788	Not outcome
257	Vlachou, M.; Drebes, A.; Candilio, L.; Weeraman, D.; Mir, N.; Murch, N.; Davies, N.; Coghlan, J. G.	Pulmonary thrombosis in Covid-19: before, during and after hospital admission	10.1007/s11239-020-02370-7	Not RCTs or observational studies without control group
258	Voicu, S.; Megarbane, B.; Bonnini, P.	Deep vein thrombosis in patients with covid-19 pneumonia. [French]	http://dx.doi.org/10.1684/stv.2020.1142	Other than English or Korean
259	Vorobyev, P. A.; Momot, A. P.; Krasnova, L. S.; Vorobiev, A. P.; Talipov, A. K.	Pathogenesis, diagnosis, prevention and treatment of disseminated intravascular coagulation syndrome in COVID-19 infection. [Russian]	http://dx.doi.org/10.26442/00403660.2020.11.000887	Other than English or Korean
260	Vorobyev, P. A.; Momot, A. P.; Krasnova, L. S.; Vorobiev, A. P.; Talipov, A. K.	[Pathogenesis, diagnosis, prevention and treatment of disseminated intravascular coagulation syndrome in COVID-19 infection]	10.26442/00403660.2020.11.000887	Other than English or Korean
261	Wada, K.; Hashimoto, Y.; Nakajima, M.; Ueda, M.	COVID-19 and stroke. [Japanese]	http://dx.doi.org/10.5692/CLINICALNEUROLOGY-001529	Other than English or Korean
262	Weeks, L. D.; Sylvestre, K. W.; Connors, J. M.; Connell, N. T.	Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study	10.1002/rth2.12521	Not comparator
263	Wei, F.; Shuai, X. X.; Chen, Z. J.; Cao, G. L.; Wang, L.; Qiu, T.; Hu, T.; Wu, L.; Zhang, Q.; Huang, H. X.; Zhang, Y. W.; Zhu, L.; Cheng, X.	[Analysis on the efficacy and safety of fibrinolytic therapy in patients with acute ST-segment elevation myocardial infarction during the COVID-19 epidemic]	10.3760/cmaj.cn112148-20200331-00268	Other than English or Korean
264	Weitz-Munoz, S.; Parra-Lucares, A.; Ili, F.; Ramos, C.; Chaigneau, E.; Llancaqueo, M.	[COVID-19 infection presenting as a myocardial infarction. Report of one case]	10.4067/s0034-98872020001201848	Other than English or Korean
265	Wenzler, E.; Engineer, M. H.; Yaqoob, M.; Benken, S. T.	Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease	10.1055/s-0040-1720962	Not comparator

(Continued to the next page)

Supplementary Table 3. Continued

#	Authors	Title	Source	Reasons for exclusion
266	Xiaopeng, S.; Lijie, Q.; Lei, Y.; Weimin, B.; Lijuan, J.; Kuikui, M.	Value of interleukin-6 and CD4+ T-lymphocytopenia in assessing the severity and prognosis of coronavirus disease 2019. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn121430-20200521-00395	Other than English or Korean
267	Xu, Y.; Qian, Y.; Gu, Q.; Tang, J.	Relationship between D-dimer concentration and inflammatory factors or organ function in patients with Coronavirus disease 2019. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn121430-20200414-00518	Other than English or Korean
268	Yao, N.; Wang, S. N.; Lian, J. Q.; Sun, Y. T.; Zhang, G. F.; Kang, W. Z.; Kang, W.	Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn501113-20200226-00070	Other than English or Korean
269	Zerwes, S.; Hernandez Cancino, F.; Liebetrau, D.; Gossiau, Y.; Warm, T.; M rki, B.; Hyhlik-D r r, A	[Increased risk of deep vein thrombosis in intensive care unit patients with COVID-19 infections?-Preliminary data]	10.1007/s00104-020-01222-7	Other than English or Korean
270	Zhang, J.; Gao, X. L.; Li, D. J.; Jiang, Y.; Liu, Y.; Pang, L.; Xu, D.; Yang, L. H.	Association of D-dimer, inflammatory markers, cytokines abnormality, and disease severity in COVID-19 severe/critical patients in Wuhan. [Chinese]	http://dx.doi.org/10.3760/cma.jissn.0253-2727.2020.11.008	Other than English or Korean
271	Zhang, J.; Gao, X. L.; Li, D. J.; Jiang, Y.; Liu, Y.; Pang, L.; Xu, D.; Yang, L. H.	[Association of D-dimer, inflammatory markers, cytokines abnormality, and disease severity in COVID-19 severe/critical patients in Wuhan]	10.3760/cma.jissn.0253-2727.2020.11.008	Other than English or Korean
272	Zhang, L. T.; Long, Y. L.; Yang, J.; Fan, Q. K.; Dai, Y. Y.; Liu, B.; Zhang, Z. L.	[Association between D-dimer levels and clinical events in patients with mechanical heart valve replacement under oral anticoagulation therapy]	10.3760/cma.jissn.0253-3758.2017.10.008	Other than English or Korean
273	Zhang, L.; Long, Y.; Yang, J.; Fan, Q.; Dai, Y.; Liu, B.; Zhang, Z.	Association between D-dimer levels and clinical events in patients with mechanical heart valve replacement under oral anticoagulation therapy. [Chinese]	http://dx.doi.org/10.3760/cma.jissn.0253-3758.2017.10.008	Other than English or Korean
274	Zhang, Y.; Cao, W.; Xiao, M.; Li, Y. J.; Yang, Y.; Zhao, J.; Zhou, X.; Jiang, W.; Zhao, Y. Q.; Zhang, S. Y.; Li, T. S.	Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia. [Chinese]	http://dx.doi.org/10.3760/cma.jissn.0253-2727.2020.008	Other than English or Korean
275	Zhang, Y.; Cao, W.; Xiao, M.; Li, Y. J.; Yang, Y.; Zhao, J.; Zhou, X.; Jiang, W.; Zhao, Y. Q.; Zhang, S. Y.; Li, T. S.	[Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia]	10.3760/cma.jissn.0253-2727.2020.008	Other than English or Korean
276	Zhang, Y.; Cao, W.; Xiao, M.; Li, Y. J.; Yang, Y.; Zhao, J.; Zhou, X.; Jiang, W.; Zhao, Y. Q.; Zhang, S. Y.; Li, T. S.	Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. [Chinese]	http://dx.doi.org/10.3760/cma.jissn.0253-2727.2020.0006	Other than English or Korean
277	Zhang, Y.; Cao, W.; Xiao, M.; Li, Y. J.; Yang, Y.; Zhao, J.; Zhou, X.; Jiang, W.; Zhao, Y. Q.; Zhang, S. Y.; Li, T. S.	[Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]	10.3760/cma.jissn.0253-2727.2020.0006	Other than English or Korean
278	Zhong, S.; Wu, F.; Peng, N.; Xie, Q.; Song, J.; Li, W.	Research progress of coagulation dysfunction in coronavirus disease 2019. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn121430-20200426-00593	Other than English or Korean
279	Zhu, J.; Zhong, Z.; Ji, P.; Pang, J.; Li, H.; Li, B.; Zhang, J.	Coagulation features of coronavirus disease 2019: a meta-analysis. [Chinese]	http://dx.doi.org/10.3760/cma.j.cn114452-20200507-00455	Other than English or Korean
280	Zinn, S.; Bauko, B.; Neb, H.; Zacharowski, K.	COVID-19: intensive care patients - current pharmacological strategies. [German]	Azneimitteltherapie 2021, 39(3):70-80.	Other than English or Korean
281	Zatloch, I.; Smudla, A.; Babik, B.; Tanczos, K.; Kobori, L.; Szabo, Z.; Fazakas, J.	[Procoagulation, hypercoagulation és fibrinolysis „shut down” kimutatása ClotPro® vizsgálóeszköztesztek segítségével COVID-19-betegekben]	10.1556/650.2020.31870	Other than English or Korean
282	Alvarez-Rodriguez, E.; Gonzalez Gonzalez, R.; Torres-Garate, R.; Lopez-Riquelme, P.; Gonzalez Martil, I.; Abad Cunado, V.	[Learning with COVID-19: what about anticoagulation?]	10.23938/assn.0884	Other than English or Korean